Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA | RVX.TO Message Board Posts

Resverlogix Corp.

  RVX.TO website
  • Create your FREE account today!



    Username:Up to 23 characters, no spaces or apostrophes allowed.

    Password:6-20 characters.

    Confirm PasswordRetype Your Password.

    Email:You will receive an email to confirm this account,so please enter a valid address (and double cheek for typos!)


    I have read and agree to the InvestorVillage User Agreement.














  • Click here to support site improvement efforts

RVX.TO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  26297 of 26335  at  1/5/2017 5:50:32 PM  by

fuzzyjr


Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

Resverlogix Announces Presentation at 9th Annual Biotech Sho
News Release Issued: Jan 5, 2017 (3:43pm MST)

Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
CALGARY, Jan. 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.

Presentation Details:

Date: January 9th
Time: 2:00pm PT
Duration: 30 minutes
Location: Room 3 (Ballroom Level) at the Hilton San Francisco Union Square

Mr. McCaffrey's presentation will be available on the Company website on the Media/Events page immediately prior to the scheduled presentation time.

To schedule a meeting with senior management in San Francisco during the event, please contact Investor Relations.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

For further information please visit www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

SOURCE Resverlogix Corp.

image: https://ci3.googleusercontent.com/proxy/JAFiEsZh3l3j8kqunBgWgBy2aNH6fi13uhB0ci17BHvt4J1BQb_jyi1YZECw64ZCQFi0GMvtm-12YZeCVW9mlEU0xF4XicNypozsjovihca69_f9w7PIC-l_qTXNRU5TUnmW1y9ToOg88AbH733eOZm8lkkD6lK7Y8ZTdlDa78_gaEd94cPF=s0-d-e1-ft#https://rt.newswire.ca/rt.gif?NewsItemId=C2222&Transmission_Id=201701051743CANADANWCANADAPR_C2222&DateId=20170105




This email is being delivered to you by:

Resverlogix Corp.
300, 4820 Richard Road SW
Calgary, AB T3E 6L1
E: info@resverlogix.com
Ph: 403-254-9252


Read more at http://www.stockhouse.com/companies/bullboard/rvxcf/resverlogix-corp?postid=25672739#cxgq7qePBvm69rAs.99


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 167
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2016 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...